Hypersomnias

SomnusNooze Articles > Hypersomnias


What’s New in the Diagnosis and Treatment of Hypersomnia in 2016?

Rather than writing our own article for this week’s edition of SomnusNooze, we are bringing you information from Dr. David Cunnington in Melbourne, Australia. Dr. Cunnington has agreed to share with us a recent post from his website (sleephub.com.au) that covers hypersomnia-related topics from the SLEEP2016...

Continue Reading

Act Today and Let Your Voice Be Heard

Very recently, the Hypersomnia Foundation became aware of an opportunity to help shape the future of sleep research. The National Institutes of Health, the primary source of funding for medical research in the United States, has issued a Request for Information, which you can view at: https://grants.nih.gov/grants/guide/notice-files/NOT-HL-16-312.html. The final date to...

Continue Reading

What Does One SOREMP Mean?

Background The primary feature of the two main central disorders of hypersomnolence—narcolepsy and idiopathic hypersomnia (IH)—is excessive daytime sleepiness, defined in the International Classification of Sleep Disorders, third edition, as “daily episodes of an irrepressible need to sleep or daytime lapses into sleep." Overnight sleep testing (polysomnography) and a...

Continue Reading

Summary of Rationale Behind and Research Studies into L-carnitine as a Treatment for Narcolepsy

Background In this 2013 study published in PLoS One, the researchers Miyagawa et al hypothesized that L-carnitine supplementation might help improve narcolepsy symptoms by increasing β-fatty-acid oxidation. Fatty acids are a major energy source for the human body. For them to be broken down and metabolized via oxidation...

Continue Reading

EMA Recommends Approval of Pitolisant for the Treatment of Narcolepsy

On November 20, 2015, the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended that Bioprojet Pharma's drug pitolisant (Wakix) be approved for the treatment of narcolepsy with or without cataplexy. In making its recommendation, the Committee reviewed data from four studies of pitolisant—two placebo-controlled...

Continue Reading

Get SomnusNooze, our e-newsletter

Sign up to receive HF updates, news from the world of sleep research, first-person stories, and more.

You will receive and email from (please check your junk/spam folder if needed) to confirm your subscription to our newsletter through MailChimp. You are not subscribed until you confirm. Thank you for your interest in Hypersomnia Foundation!